These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

94 related items for PubMed ID: 10026844

  • 1. Inhibition of tumorigenesis in a murine B-cell lymphoma transplant model by c-Myc complementary oligonucleotides.
    Smith JB, Wickstrom E.
    Adv Exp Med Biol; 1998; 451():17-22. PubMed ID: 10026844
    [No Abstract] [Full Text] [Related]

  • 2. Antisense c-myc and immunostimulatory oligonucleotide inhibition of tumorigenesis in a murine B-cell lymphoma transplant model.
    Smith JB, Wickstrom E.
    J Natl Cancer Inst; 1998 Aug 05; 90(15):1146-54. PubMed ID: 9701364
    [Abstract] [Full Text] [Related]

  • 3. Antisense oligodeoxynucleoside methylphosphonate inhibition of mouse c-myc p65 protein expression in E mu-c-myc transgenic mice.
    Wickstrom E, Bacon TA, Wickstrom EL, Werking CM, Palmiter RD, Brinster RL, Sandgren EP.
    Nucleic Acids Symp Ser; 1991 Aug 05; (24):151-4. PubMed ID: 1841270
    [Abstract] [Full Text] [Related]

  • 4. Antisense c-myc inhibition of lymphoma growth.
    Wickstrom E.
    Antisense Nucleic Acid Drug Dev; 1997 Jun 05; 7(3):225-8. PubMed ID: 9212915
    [No Abstract] [Full Text] [Related]

  • 5. Prevention of tumor formation in a mouse model of Burkitt's lymphoma by 6 weeks of treatment with anti-c-myc DNA phosphorothioate.
    Huang Y, Snyder R, Kligshteyn M, Wickstrom E.
    Mol Med; 1995 Sep 05; 1(6):647-58. PubMed ID: 8529131
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of the translocated c-myc in Burkitt's lymphoma by a PNA complementary to the E mu enhancer.
    Cutrona G, Carpaneto EM, Ponzanelli A, Ulivi M, Millo E, Scarfì S, Roncella S, Benatti U, Boffa LC, Ferrarini M.
    Cancer Res; 2003 Oct 01; 63(19):6144-8. PubMed ID: 14559793
    [Abstract] [Full Text] [Related]

  • 7. Lymphoid and non-lymphoid tumors in E kappa-myc transgenic rabbits.
    Sethupathi P, Spieker-Polet H, Polet H, Yam PC, Tunyaplin C, Knight KL.
    Leukemia; 1994 Dec 01; 8(12):2144-55. PubMed ID: 7808003
    [Abstract] [Full Text] [Related]

  • 8. Silencing of human c-myc oncogene expression by poly-DNP-RNA.
    Shen L, Zhang C, Ambrus JL, Wang JH.
    Oligonucleotides; 2005 Dec 01; 15(1):23-35. PubMed ID: 15788898
    [Abstract] [Full Text] [Related]

  • 9. Cell populations during tumorigenesis in Eu-myc transgenic mice.
    Sidman CL, Shaffer DJ, Jacobsen K, Vargas SR, Osmond DG.
    Leukemia; 1993 Jun 01; 7(6):887-95. PubMed ID: 8501983
    [Abstract] [Full Text] [Related]

  • 10. H-2/myc, E mu/myc, and c-myc transgenic mice: potent sources of early hematopoietic cell lines.
    Roland J, Morello D.
    Cell Growth Differ; 1993 Nov 01; 4(11):891-900. PubMed ID: 8297795
    [Abstract] [Full Text] [Related]

  • 11. Role of c-myc and CD45 in spontaneous and anti-receptor-induced apoptosis in adult murine B cells.
    Scott DW, Lamers M, Köhler G, Sidman CL, Maddox B, Carsetti R.
    Int Immunol; 1996 Sep 01; 8(9):1375-85. PubMed ID: 8921415
    [Abstract] [Full Text] [Related]

  • 12. Lymphoma models for B cell activation and tolerance. X. Anti-mu-mediated growth arrest and apoptosis of murine B cell lymphomas is prevented by the stabilization of myc.
    Fischer G, Kent SC, Joseph L, Green DR, Scott DW.
    J Exp Med; 1994 Jan 01; 179(1):221-8. PubMed ID: 8270867
    [Abstract] [Full Text] [Related]

  • 13. B-cell tumorigenesis in mice carrying a yeast artificial chromosome-based immunoglobulin heavy/c-myc translocus is independent of the heavy chain intron enhancer (Emu).
    Palomo C, Zou X, Nicholson IC, Bützler C, Brüggemann M.
    Cancer Res; 1999 Nov 01; 59(21):5625-8. PubMed ID: 10554044
    [Abstract] [Full Text] [Related]

  • 14. Transgenic N-myc mouse model for indolent B cell lymphoma: tumor characterization and analysis of genetic alterations in spontaneous and retrovirally accelerated tumors.
    Sheppard RD, Samant SA, Rosenberg M, Silver LM, Cole MD.
    Oncogene; 1998 Oct 22; 17(16):2073-85. PubMed ID: 9798678
    [Abstract] [Full Text] [Related]

  • 15. A human immunoglobulin gene reduces the incidence of lymphomas in c-Myc-bearing transgenic mice.
    Nussenzweig MC, Schmidt EV, Shaw AC, Sinn E, Campos-Torres J, Mathey-Prevot B, Pattengale PK, Leder P.
    Nature; 1988 Dec 01; 336(6198):446-50. PubMed ID: 3143076
    [Abstract] [Full Text] [Related]

  • 16. Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models.
    Pastorino F, Brignole C, Marimpietri D, Pagnan G, Morando A, Ribatti D, Semple SC, Gambini C, Allen TM, Ponzoni M.
    Clin Cancer Res; 2003 Oct 01; 9(12):4595-605. PubMed ID: 14555535
    [Abstract] [Full Text] [Related]

  • 17. Analysis of wild-type and mutant SL3-3 murine leukemia virus insertions in the c-myc promoter during lymphomagenesis reveals target site hot spots, virus-dependent patterns, and frequent error-prone gap repair.
    Nielsen AA, Sørensen AB, Schmidt J, Pedersen FS.
    J Virol; 2005 Jan 01; 79(1):67-78. PubMed ID: 15596802
    [Abstract] [Full Text] [Related]

  • 18. E mu N- and E mu L-myc cooperate with E mu pim-1 to generate lymphoid tumors at high frequency in double-transgenic mice.
    Möröy T, Verbeek S, Ma A, Achacoso P, Berns A, Alt F.
    Oncogene; 1991 Nov 01; 6(11):1941-8. PubMed ID: 1658705
    [Abstract] [Full Text] [Related]

  • 19. Strain-dependency of chromosomal abnormalities in lymphomas developed in E mu-myc transgenic mice.
    Akagi K, Yamamura K.
    Jpn J Cancer Res; 2001 May 01; 92(5):499-505. PubMed ID: 11376558
    [Abstract] [Full Text] [Related]

  • 20. Preclinical antisense DNA therapy of cancer in mice.
    Smith JB, Wickstrom E.
    Methods Enzymol; 2000 May 01; 314():537-80. PubMed ID: 10565038
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.